Novak, D.; Janota, B.; Hörmann, A.A.; Sawicka, A.; Kroselj, M.; Hubalewska-Dydejczyk, A.; Fani, M.; Mikolajczak, R.; Kolenc, P.; Decristoforo, C.;
et al. Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 2023, 15, 885.
https://doi.org/10.3390/pharmaceutics15030885
AMA Style
Novak D, Janota B, Hörmann AA, Sawicka A, Kroselj M, Hubalewska-Dydejczyk A, Fani M, Mikolajczak R, Kolenc P, Decristoforo C,
et al. Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 2023; 15(3):885.
https://doi.org/10.3390/pharmaceutics15030885
Chicago/Turabian Style
Novak, Doroteja, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo,
and et al. 2023. "Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study" Pharmaceutics 15, no. 3: 885.
https://doi.org/10.3390/pharmaceutics15030885
APA Style
Novak, D., Janota, B., Hörmann, A. A., Sawicka, A., Kroselj, M., Hubalewska-Dydejczyk, A., Fani, M., Mikolajczak, R., Kolenc, P., Decristoforo, C., & Garnuszek, P.
(2023). Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics, 15(3), 885.
https://doi.org/10.3390/pharmaceutics15030885
